The European Patent Office (EPO) has issued a European patent covering combinations of Sunesis Pharmaceuticals’ drug candidate voreloxin with cytarabine.

Cytarabine is the standard-of-care treatment for Acute Myeloid Leukemia (AML), a rapidly progressing cancer, and the therapy is used in combination with voreloxin in a Phase 2 trial in AML patients.

Sunesis said it plans to begin a Phase 3 trial of voreloxin in combination with cytarabine in patients with relapsed/refractory AML in the second half of this year.

The European patent will give patent coverage for the combination product in 30 member states of the European Patent Convention up to 2025.

The biopharmaceutical company is looking at developing and commercialising the new oncology therapeutics for the treatment of solid and hematologic cancers.